MerLion's lead drug finafloxacin moves into Phase III through Alcon
This article was originally published in Scrip
MerLion Pharmaceuticals' most advanced therapeutic product, the broad-spectrum fluoroquinolone antibiotic finafloxacin, has moved into its first Phase III clinical trials, in the US and Canada for the treatment of ear infections.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.